SMART MONEY GROUP

[BioSpecialist]

(ETON) First FDA Decision in 10 Days if approved stock likely to jump above $11+ especially because of its very low float .Market Cap only $139 million at $7.90 share price .GL

EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019.

EM-100 Ophthalmic Solution

•Innovative over-the-counter ophthalmic solution for treatment of allergic conjunctivitis

•If approved, EM-100 would be the first preservative-free ophthalmic product indicated for allergic conjunctivitis

•Product has been filed with the FDA and is expected to be approved in 2019

•U.S. allergic conjunctivitis ophthalmic market is >$600 million annually

•Eton partnered with Bausch Health for commercialization

•Eton receives additional milestone payment upon approval and a royalty on net sales